News|Articles|November 17, 2026

Secukinumab Receives FDA Approval for Polymyalgia Rheumatica

Fact checked by: Patrick Campbell

Secukinumab 150 mg doubled week-52 sustained remission vs placebo in REPLENISH, making it the first anti-IL-17 biologic approved for PMR.

The US Food and Drug Administration (FDA) has approved secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica (PMR) with an inadequate response to corticosteroids or intolerance of a corticosteroid taper, Novartis announced on November 17, 2026.1

Secukinumab, a fully human monoclonal antibody inhibiting interleukin-17A (IL-17A), is the first anti-IL-17 biologic approved in PMR and now carries 11 US indications.1 Glucocorticoids remain the standard of care, yet relapses affect up to 40% of patients in the first year, and long-term exposure raises the risk of osteoporosis, cardiovascular disease, and diabetes, according to the company.1 The indication is already approved in the European Union, with additional regulatory reviews ongoing in Japan and other countries.1

“The FDA approval of secukinumab in PMR marks a significant advancement for patients and physicians. Patients with PMR are at increased risk of poor outcomes related to steroids, and the prospect of months or years of additional steroids is disheartening,” said John Stone, MD, MPH, professor of medicine, Harvard Medical School, Massachusetts General Hospital, and global principal investigator for the REPLENISH trial. “For too long, treatment options beyond glucocorticoids have been limited. In the Phase III REPLENISH trial, secukinumab doubled the likelihood of sustained remission while helping patients taper off steroids, which should be the goal of PMR treatment.”

Secukinumab efficacy in the phase 3 REPLENISH trial

REPLENISH (NCT05767034) was a multicenter, randomized, double-blind, placebo-controlled phase 3 trial conducted across 27 countries in patients with recently relapsed PMR.1,2 A total of 381 patients were randomized 1:1:1 to secukinumab 300 mg, secukinumab 150 mg, or placebo for 52 weeks, with all groups receiving a 24-week prednisone taper.2 FDA approval covers the 150 mg dose.1

The primary endpoint was sustained remission at week 52, defined as the absence of PMR signs or symptoms and no new giant cell arteritis diagnosis warranting escape or rescue treatment, maintained from week 12 through week 52.2 Sustained remission occurred in 40.6% (95% CI, 32.2-49.0) of the secukinumab 150 mg group and 41.2% (95% CI, 32.8-49.7) of the 300 mg group vs 20.4% (95% CI, 13.6-27.2) of the placebo group (P < .001 for each dose vs placebo).2

The results were published in the New England Journal of Medicine and presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress on June 3, 2026.2,3

Glucocorticoid-sparing effects and safety of secukinumab in PMR

Key secondary endpoints included complete sustained remission at week 52, adjusted annual cumulative glucocorticoid dose, and time to first escape or rescue treatment through week 52.1 The mean adjusted annual cumulative glucocorticoid dose was 1683.2 mg with secukinumab 150 mg and 1603.7 mg with secukinumab 300 mg, compared with 2093.0 mg with placebo.2

Key Takeaways

What is secukinumab approved for in polymyalgia rheumatica?

Secukinumab 150 mg is approved for adults with PMR who have had an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper.

How does secukinumab work?

Secukinumab is a fully human monoclonal antibody selectively inhibiting IL-17A, a cytokine involved in inflammation across multiple immune-mediated diseases.

What did the REPLENISH trial show?

With a 24-week prednisone taper, sustained remission at week 52 occurred in 40.6% of patients receiving secukinumab 150 mg vs 20.4% receiving placebo, with a lower annual cumulative glucocorticoid dose.

Serious adverse events occurred in 15.9% of the 150 mg group, 13.5% of the 300 mg group, and 14.2% of the placebo group.2 With the 150 mg dose, hypersensitivity reactions, including eczema, dermatitis, rash, and urticaria, occurred in 14% of patients vs 9% with placebo, and urinary tract infections (UTIs) occurred in 13% vs 7%, respectively.1 Nasopharyngitis, fungal infections, and back pain were also more common with secukinumab than with placebo.2

One patient in the 150 mg group had a serious UTI, and a fatal case of cryptococcal meningitis occurred in a secukinumab-treated patient.1 Novartis characterized the safety profile in PMR as consistent with the established profile of secukinumab.1

“PMR can make remarkably ordinary things hard: getting out of bed, getting dressed, lifting your arms, getting through the day. For years, patients have had too few treatment options,” said Seth Ginsberg, cofounder and president, Global Healthy Living Foundation and CreakyJoints. “The approval of secukinumab offers patients and their clinicians a new therapeutic option and the opportunity for more individualized care.”

Secukinumab is also approved for psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, nonradiographic axial spondyloarthritis, and hidradenitis suppurativa, along with several pediatric indications.1 The approval adds an IL-17A-targeted option alongside sarilumab (Kevzara), an interleukin-6 receptor antagonist previously approved for PMR.

References
  1. Novartis. Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR). Published November 17, 2026. Accessed November 17, 2026. https://www.novartis.com/news/media-releases/novartis-cosentyx-becomes-first-and-only-fda-approved-anti-il-17-biologic-people-polymyalgia-rheumatica-pmr
  2. Stone JH, Buttgereit F, Saraux A, et al. Phase 3 trial of secukinumab in polymyalgia rheumatica. N Engl J Med. 2026;395(7):637-647. doi:10.1056/NEJMoa2602567. https://doi.org/10.1056/NEJMoa2602567
  3. Dejaco C, et al. Secukinumab in polymyalgia rheumatica: results of the phase 3 REPLENISH trial. Presented at: European Congress of Rheumatology (EULAR) 2026; June 3-6, 2026; London, UK.

Related to this article